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Patients deﬁcient in the cytoskeletal regulator Wiskott–Aldrich syndrome protein (WASp)
are predisposed to varied autoimmunity, suggesting it has an important controlling role
in participating cells. IL-10-producing regulatory B (Breg) cells are emerging as impor-
tant mediators of immunosuppressive activity. In experimental, antigen-induced arthritis
WASp-deﬁcient (WASp knockout [WAS KO]) mice developed exacerbated disease asso-
ciated with decreased Breg cells and regulatory T (Treg) cells, but increased Th17 cells
in knee-draining LNs. Arthritic WAS KO mice showed increased serum levels of B-cell-
activating factor, while their B cells were unresponsive in terms of B-cell-activating factor
induced survival and IL-10 production. Adoptive transfer of WT Breg cells ameliorated
arthritis in WAS KO recipients and restored a normal balance of Treg and Th17 cells. Mice
with B-cell-restricted WASp deﬁciency, however, did not develop exacerbated arthritis,
despite exhibiting reduced Breg- and Treg-cell numbers during active disease, and Th17
cells were not increased over equivalent WT levels. These ﬁndings support a contribu-
tory role for defective Breg cells in the development of WAS-related autoimmunity, but
demonstrate that functional competence in other regulatory populations can be com-
pensatory. A properly regulated cytoskeleton is therefore important for normal Breg-
cell activity and complementation of defects in this lineage is likely to have important
therapeutic beneﬁts.
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Additional supporting information may be found in the online version of this article at the
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Introduction
The Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary
immunodeﬁciency resulting from mutations in the gene encoding
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the Wiskott–Aldrich syndrome protein (WASp), a key regulator of
the actin cytoskeleton in immune cells. Patients with WAS typ-
ically display recurrent infections, microthrombocytopenia, and
eczema as well as a predisposition to develop autoimmunity and
lymphoproliferative disease [1, 2]. Although 40–70% of patients
with classical disease have been reported to develop autoimmu-
nity [3, 4], little is known about the underlying mechanisms
and its development is likely to be multifactorial and related to
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dysfunction of different hematopoietic compartments [5]. Several
studies have revealed functional deﬁciency of natural T regula-
tory cells in both mouse models and human WAS patients [6–9].
However, subsets of B cells have also emerged as important alter-
native regulators of autoimmunity (B regulatory cells, Breg). For
example, mice are unable to resolve inﬂammation in experimen-
tal autoimmune encephalomyelitis (EAE) in the absence of IL-10
provided by autoreactive B cells [10, 11]. In addition, in models
of arthritis and colitis, IL-10-producing B cells have been shown
to possess disease modulating capability [12, 13]. Transfer of
CD21hiCD23hiCD1dhi transitional 2 marginal zone precursor (T2-
MZP) B cells isolated either from na¨ ıve mice or from mice in
the resolution phase of antigen-induced arthritis was sufﬁcient
to prevent the development of arthritis [14]. T2-MZP Breg cells
are profoundly depleted in MRL/lpr mice with established sys-
temic lupus erythematosus [15]. Similarly, Breg cells, identiﬁed as
CD5+CD1dhi B cells (B10 Breg cells), have been found to directly
modulate EAE and murine systemic lupus erythematosus [16–18].
WASp-deﬁcient (WASp knockout [WAS KO]) mice have signiﬁ-
cantlyreducednumbersofmarginalzone(MZ)BcellsandT2-MZP
B cells reﬂecting marked disturbances of development and home-
ostasis of mature B-cell subsets [19–21]. We therefore postulated
that deﬁciency of Breg-cell function may contribute signiﬁcantly
to the autoimmune phenotype of WAS and used an experimental
model of antigen-induced arthritis to investigate the contribution
of Breg cells to WAS-related autoimmunity.
Results
Development of exacerbated experimental arthritis in
WAS KO mice
To study the development of autoimmune disease in WAS KO
mice, we employed an experimental model of antigen-induced
arthritis. Arthritis was induced by immunization with methylated
BSA (mBSA), followed by intraarticular mBSA challenge. WAS KO
mice developed exacerbated arthritis as shown by the accumula-
tion of mononuclear cells in the knee joint compared with those
in C57BL/6 animals (Fig. 1A). This was accompanied by clinically
more severe disease as assessed by a standardized walking score
(Fig. 1B) and measurement of knee joint swelling (Fig. 1C). There
was a highly signiﬁcant positive correlation between the walking
score and the amount of swelling observed in the mBSA-injected
knee (Supporting Information Fig. 1A).
Decreased numbers of Breg and Treg cells and
increased Th17 cells in arthritic WAS KO mice
Next, we analyzed immune cell populations in the draining LNs
of both the control and mBSA-injected knee joints. We observed
a signiﬁcant reduction in the number of both B220+IL-10+ cells
(Fig. 2A and B) and CD4+FoxP3+ Treg cells (Fig. 2C and D) in
WAS KO mice compared with those in C57BL/6 mice. The per-
centage of IL-10-producing B cells was also signiﬁcantly reduced
in spleens of arthritic WAS KO mice, whereas Treg-cell percent-
ages were normal (Fig. 2E and F). This is consistent with previ-
ous reports showing a variable defect of Treg-cell number with
the most pronounced reduction in local LNs [6–9]. There was an
inverse correlation between the number of B220+IL-10+ Bc e l l s
and Treg cells in the mBSA-knee-draining LNs and the severity
of disease, both as an objective walking score and as the level of
swelling observed in the mBSA-treated knee (Supporting Informa-
tion Fig. 1B–E). Consistent with dampened Th1 response in IL-10+
B-cell sufﬁcient arthritic WT C57BL/6 mice [14], we observed a
trend for increased Th1 IFN-γ production (Fig. 2G) and signiﬁ-
cantly reduced Th2 IL-10 production by CD4+ T cells from WAS
KO mice (Fig. 2H). No signiﬁcant differences were observed for
IFN-γ production by CD8+ T cells (Fig. 2I).
As an important role in the development of autoimmune dis-
ease has been identiﬁed for IL-17-producing T (Th17) cells, we
analyzed Th17 cells and found a signiﬁcant increase of Th17 cells
in LNs of mBSA-treated knees of WAS KO mice (Fig. 2J and K).
In the spleen, Th17 cells were also found in greater numbers
(Fig. 2L) and the number of Th17 cells correlated positively with
the severity of disease (Supporting Information Fig. 1F–G).
Reduced Breg cells under noninﬂammatory conditions
IL-10-producing Breg cells have been found to be able to modulate
autoimmune disease by affecting the frequency and equilibrium
of both Treg cells and Th17 cells [22]. Chimeric mice speciﬁcally
lacking IL-10-producing B cells developed augmented arthritis,
whichwasaccompaniedbyadecreaseofTregcellsandanincrease
of Th1 and Th17 cells [22]. These ﬁndings therefore mirror our
observations in WAS KO mice and suggest a numerical or func-
tional deﬁciency. As in previous studies [19–21], we also observed
a signiﬁcant reduction in the number of B220+CD21+CD23− MZ
and also B220+CD21+CD23+ T2-MZP B cells (Fig. 3A), with the
latter containing Breg cells as identiﬁed by their IL-10 produc-
tion (Fig. 3B). As plasmacytoid DCs are also known to express
B220 in mice, we also used CD19 to identify B cells and observed
similar results (data not shown). In addition, when we identiﬁed
Breg cells as CD19+CD5+CD1dhi (B10 Breg) cells these were also
reduced in number (Supporting Information Fig. 2A–B). These
ﬁndings indicate that under noninﬂammatory conditions, B cells
that have been identiﬁed to have regulatory activity are deﬁcient
in WAS KO mice.
In humans, a circulating CD19+CD24hiCD38hi B-cell subset has
been recently described that possesses regulatory function par-
tially via provision of IL-10 [23]. Enumeration of this subset in
younger children is complicated by the fact that these markers
are shared with CD19+CD27−CD10+CD38hi recent BM emigrant
B cells, the frequency of which is higher at an early age (Support-
ing Information Fig. 3) [24]. These markers alone therefore do
not reliably identify a Breg population. We therefore stimulated
PBMCs for 48 h with CpG and analyzed IL-10 production, which
closely deﬁnes the population of B cells with regulatory activity. As
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Figure 1. WAS KO mice develop exacerbated experimental arthritis. (A) H&E stainings of knee joints for cellular inﬁltrates in C57BL/6 and WAS KO
mice, indicated by asterisks. Representative images are shown from day 7; cart: articular cartilage; ep: epiphyseal plate; fp: fat pad; lig: ligament.
Scale bar 500 μm. (B, C) Severity of arthritis was assessed as (B) a clinical walking score and (C) knee swelling. Data are shown as mean ± SEM
of nine animals per group up to day 4, and four animals per group at day 7; data are from a single experiment. *p < 0.05, **p < 0.01, ***p < 0.001,
unpaired Student’s t-test.
before, we observed that the CD24hiCD38hi B cells produced the
most IL-10 (Fig. 3C) [23]. WAS patients (characterized by absent
WASp expression, see Supporting Information Table 1) exhibited
a signiﬁcant reduction of IL-10-producing CD24hiCD38hi Bc e l l s
(Fig. 3C–E), suggesting that there is a similar deﬁciency of B cells
with regulatory activity to that observed in mice.
Increased B-cell-activating factor levels, but
unresponsiveness to BAFF stimulation in
WAS KO mice
B-cell-activating factor (BAFF) is an important signal promoting
survival and differentiation of peripheral B cells. Mice transgeni-
cally overexpressing BAFF show a marked increase in transitional
T2 and MZ B-cell numbers, while BAFF−/− mice have strongly
reduced numbers of transitional T2 and MZ B cells as well as fol-
licular B cells [25, 26]. Furthermore, treatment of B cells with
BAFF was shown to induce IL-10 production and a regulatory
phenotype [27]. As WAS KO mice have reduced MZ B and Breg
cells, we set out to analyze whether defective BAFF production or
function is involved. When we analyzed serum levels of BAFF, we
however, found that BAFF levels in WAS KO mice were increased.
This was most pronounced and signiﬁcant in arthritic mice, while
under noninﬂammatory conditions there was a trend for increased
serum BAFF (Fig. 4A). These ﬁndings were unexpected, as we
would have expected increased MZ B and Breg cells in the pres-
ence of elevated BAFF levels [25, 27]. We therefore investigated
whetherWASKOBcellsareresponsive toBAFFstimulation. When
we stimulated B cells with BAFF, we observed that in contrast to
WT B cells, WAS KO B cells do not produce IL-10, show reduced
survival and fail to upregulate BAFF receptor expression (Fig. 4B–
D). These ﬁndings suggest that WAS KO B cells fail to effectively
respond to BAFF stimulation and could indicate that the increased
serum levels of BAFF reﬂect an uncoupling of a feedback mecha-
nism regulating BAFF-mediated B-cell maturation.
Adoptive transfer of Breg cells ameliorated disease
To investigate whether the reduction in Breg cells contribute
directly to altered Treg- and Th17-cell equilibrium and exacer-
bated arthritis in WAS KO mice, we isolated B220+CD21+CD23+
T2-MZP B cells from C57BL/6 mice with arthritis and adoptively
transferred these into WAS KO mice prior to arthritis induction.
Due to the low number of T2-MZP B cells present in WAS KO
mice, we were only able to isolate and sort sufﬁcient number of
cellsfromcontrolC57BL/6miceforadoptivetransferexperiments.
TransferofBregcellsintoWASKOmiceameliorateddiseasedevel-
opment signiﬁcantly as shown by the reduced knee swelling and
improved ability of the animals to walk (Fig. 5A and B). Transfer
of Breg cells into C57BL/6 animals also showed a modest but sig-
niﬁcant amelioration of disease severity (Fig. 5A and B), as has
been reported previously [14, 22]. After transfer of Breg cells, we
observed an increase in the absolute number of Treg cells (Fig. 5C)
and a reduction in the number of Th17 cells in draining LNs of
WAS KO mice (Fig. 5D). The number of Breg cells also increased
(Fig. 5E), although our analysis did not allow us to distinguish
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Figure 2. Decreased Breg cells and Treg cells and increased Th17 cells in experimental arthritis in WAS KO mice. (A) Breg cells were identiﬁed as
B220+ cells expressing IL-10 by ﬂow cytometry. IgG controls are shown in rightmost panels; (B) the data are presented as absolute cell numbers.
(C) FoxP3 expression identiﬁed CD4+ Treg cells, IgG controls shown in rightmost panels; (D) the data are presented as absolute cell numbers.
(E) Splenic Breg cells and (F) splenic Treg cells were analyzed by ﬂow cytometry. (G) Quantiﬁcation of IFN-γ-expressing CD4+ T cells, (H) IL-10-
expressing CD4+ T cells, and (I) IFN-γ-expressing CD8+ T cells by ﬂow cytometry. (J) Differential expression of IL-17 and IFN-γ, based on IgG
controls (rightmost panel), of CD4+ lymphocytes was used to analyze and (K, L) quantify the presence of Th17 cells in (K) LNs or (L) spleen. Dot
plots represent day 4 data and statistical signiﬁcance was determined by Student’s t-test. (B, D, G–I, K) Each symbol represents an individual mouse
and bars represent means, from a single performed experiment. (E–F, L) Data are shown as mean ± SEM of n = 5 at day 4 and n = 4a td a y7f r o ma
single experiment.
whether this increase reﬂected the transferred cells or whether
endogenous Breg cells were also induced. Transfer of Breg cells
into WAS KO mice appeared to inhibit the Th1 response, although
no effect on Th2 cytokine response was observed (Fig. 5F–H). Our
ﬁndings suggest that transfer of WT Breg cells at least partially
overcomes the intrinsic Breg-cell deﬁciency of WAS KO mice.
B-cell-restricted WASp deﬁciency is not sufﬁcient to
cause severe disease
Next, we set out to investigate whether the exacerbated arthritis
is due to B-cell intrinsic defects. For this we used the novel model
of B-cell selective WASp deﬁciency that was generated by crossing
mice that have the WAS locus ﬂoxed by homologous recombina-
tion with mb1-Cre knock-in mice [28] These mice have a selec-
tive and efﬁcient deletion of the WAS locus in the B-cell lineage
effectively eliminating WASp expression (Supporting Information
Fig. 4A) and, similar to WAS KO mice, exhibit reduced numbers
of MZ B cells [28] and Breg cells (Fig. 6A–E). Similar to mice with
full WASp deﬁciency (Fig. 4A), serum levels of BAFF tended to
be increased under noninﬂammatory conditions in B/cWKO mice
(8.06 ± 1.61 ng/mL, n = 5). After induction of arthritis, sur-
prisingly, we found that B/cWKO mice develop disease of similar
clinical severity as WT C57BL/6 mice (Fig. 7A and B). Analysis
of knee-draining LNs, however, showed that B/cWKO mice show
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Figure 3. Fewer Breg cells under naive, noninﬂammatory conditions in spleens of WAS KO mice and blood of WAS patients. (A) Expression of
CD21 and CD23 on B220+ B cells identiﬁed marginal zone (MZ) B and T2-MZP Breg cells (Breg, left). (B) Flow cytometric analysis of IL-10-producing
B220+ B cells (IgG control left, IL-10 right). (C, D) Human B-cell subsets were gated as (i) CD24hiCD38−, (ii) CD24hiCD38hi, and (iii) CD24intCD38int cells
and their IL-10 expression was analyzed in (C) healthy volunteers and (D) WAS patients. Top right panel shows IgG control. (E) Quantiﬁcation of
IL-10-expressing B cells as shown in (C–D). (A, B) Data are shown as representative plots and mean ± SEM of n = 6 pooled from three experiments.
(C–E) Data are shown as representative plots and with each symbol representing an individual healthy volunteer (n = 4) or WAS patient (n = 3),
pooled from two experiments; bar represents mean. Statistical signiﬁcance determined by unpaired Student’s t-test.
reduced numbers of Breg and Treg cells, similar to WAS KO mice,
but no increase in Th17 cells (Fig. 7C–E). Serum BAFF levels in
arthritic B/cWKO mice were also increased (9.80 ± 0.26 ng/mL,
n = 3, p < 0.05 compared with those in C57BL/6, see Fig. 4A),
similar to WAS KO mice. In contrast, Th1 and Th2 responses in
B/cWKO mice showed a phenotype that resembled WT C57BL/6
rather than WAS KO mice (Fig. 7F–H). These results indicate that
deﬁciency of WASp restricted to B cells was sufﬁcient to gen-
erate defective Breg- and Treg-cell responses, but insufﬁcient to
causesevereTh17-mediateddisease.Undernoninﬂammatorycon-
ditions, Treg-cell numbers in B/cWKO mice were not signiﬁcantly
different from WT in spleen (Fig. 7I) and LNs (Fig. 7J) and sup-
pressive function of B/cWKO Treg cells was found to be normal
(Supporting Information Fig. 4B). This would suggest that mod-
ulation of Treg-cell numbers by B/cWKO Breg cells is speciﬁc to
disease development, but may not be sufﬁcient to modulate Treg-
cell function.
Discussion
Development of autoimmunity is a signiﬁcant complication in the
WAS with an incidence of 40–70% in patients reported [3, 4]. In
addition, a large number of patients with mixed/split chimerism
after hematopoietic stem cell transplantation develop autoimmu-
nity, although the etiology and relationship, if any, to residual
WASp deﬁciency is unclear [29, 30]. Here, we have studied the
potentialcontributionofBregcellstothecontrolofimmunehome-
ostasis as MZ B cells are known to be signiﬁcantly reduced in WAS
KO mice and humans [19–21] and have recently been ascribed
regulatory activity through IL-10 production [31]. Under non-
inﬂammatory steady state conditions, WAS KO mice had fewer
Breg cells in spleen, determined as IL-10-producing B cells and
immunophenotypically as part of a CD21+CD23+ T2-MZP pop-
ulation. Furthermore, the numerical reduction in Breg cells was
mimicked in the blood of WAS patients, where we observed a
reduction in the number of IL-10-producing B cells. Here, we have
used an experimental arthritis model to investigate autoimmu-
nity in WAS KO mice. We observed that WAS KO mice developed
exacerbatedarthritis,whichcorrelatedwithadecreaseinBregand
Treg cells and increase in Th17 cells in draining LNs and spleen.
Furthermore, there was a trend for Th1 cells to also be increased in
WAS KO mice. Using adoptive transfer, we found that restoration
of Breg-cell activity in the early phase of arthritis development
led to an increase in the number of Treg cells and concomitant
decrease in the number of Th17 cells, resulting in ameliorating of
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Figure 4. Increased serum BAFF levels
in WAS KO mice, but unresponsiveness
of WAS KO B cells to BAFF stimulation.
(A) Serum levels of BAFF in healthy and
arthritic C57BL/6 and WAS KO mice were
measured by ELISA. (B) IL-10 expression in
response to BAFF concentration in C57BL/6
and WAS KO mice was measured by ﬂow
cytometric analysis. (C) B-cell survival and
(D) BAFF-R expression relative to 0 ng/mL
BAFFwasdeterminedbyﬂowcytometry.(A)
Data are shown as mean + SEM of n = 8
C57BL/6 and n = 6 WAS KO mice for steady
state and n = 3 for arthritic mice. (B–D) Data
are shown as mean + SEM of n = 4, (C) n = 5
and (D) n = 6m i c ep o o l e df r o mt h r e ee x p e r -
iments. Statistical signiﬁcance determined
by unpaired Student’s t-test.
disease. This exactly mirrors our previous ﬁndings using chimeric
mice speciﬁcally lacking IL-10-producing B cells that showed exac-
erbated autoimmune disease, reduced Treg cells, and increased
Th1- and Th17-cell numbers [22]. In this model, transfer of WT
CD21+CD23+ T2-MZP Breg cells (but not CD21+CD23− MZ or
CD21intCD23int follicular B-cell subsets) also increased Treg cells
and reduced Th1- and Th17-cell frequencies resulting in inhibi-
tion of inﬂammation. These ﬁndings suggest a prominent role for
IL-10-producing Breg cells in modulating disease severity and for
control of autoimmune of autoinﬂammatory processes.
In contrast to WAS KO mice, mice with B-cell-speciﬁc WASp
deﬁciency [28] surprisingly showed a milder disease phenotype
similar to WT C57BL/6 mice, despite showing a reduction in
the number of Breg and Treg cells in the LNs draining affected
knees. However, contrary to WAS KO mice, we did not ﬁnd
increased numbers of Th17 cells in the knee-draining LNs of
arthritic B/cWKO mice, suggesting that other regulatory compart-
ments are compensating. For example, WAS KO mice have defec-
tive Treg-cell function [6–9], whereas in the B/cWKO model, Treg
cells express WASp normally and have normal intrinsic function-
ality. Furthermore, under noninﬂammatory conditions, Treg-cell
numbers in both B/cWKO and WAS KO mice were found to be
normal in spleen and only slightly (not signiﬁcantly) reduced
in LNs. Our ﬁndings are therefore supportive of a role for Breg
cells modulating the number of Treg cells during a state of active
immune activity and are consistent with previous observations for
such a role of Breg cells in other experimental arthritis models
[14, 22], and also in allergen-induced airway inﬂammation and
EAE [32, 33]. The precise contribution of Treg cells in experimen-
tal arthritis in WASp deﬁciency remains to be investigated. Fur-
thermore, both intrinsic T-cell differentiation [34, 35] and extrin-
sic T-cell priming by antigen-presenting DCs [36, 37] are known
to be defective in WASp deﬁciency, which may contribute to the
aberrant induction of Th17 cells. Th17 cells are known to play
an important role for arthritis severity and progression [38] and
our data supports a key role for these cells in the development of
severe arthritis in WASp deﬁciency.
We observed increased serum levels of BAFF in both WAS KO
and B/cWKO mice and increased serum BAFF expression was also
recently reported in WAS patients [39]. Overexpression of BAFF
in mice results in a marked increase in transitional T2 and MZ
B-cell numbers, while BAFF−/− mice show reduced numbers of
transitional T2 and MZ B cells [25, 26]. Increased BAFF levels
in WAS KO mice were therefore unexpected. However, WAS KO
B cells appeared to exhibit reduced responsiveness to BAFF stim-
ulation, which would suggest that the increased serum levels of
BAFF, in particular in arthritic mice could be part of a failing feed-
back mechanism attempting to increase the number of mature
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Figure 5. Transfer of T2 Breg cells ameliorates the development of arthritis in WAS KO mice. (A, B) Severity of experimental arthritis was assessed
after Breg-cell transfer as (A) clinical walking score and (B) knee swelling. Data are shown as mean ± SEM from one experiment with control (PBS
injected) n = 5, T2 Breg n = 4, #C57BL/6 PBS versus WAS KO PBS, ##C57BL/6 Breg versus WAS KO Breg, *C57BL/6 PBS versus C57BL/6 Breg, **WAS
KO PBS versus WAS KO Breg (one-way ANOVA of AUC, p < 0.05). (C–H) The indicated cell populations in the draining LNs of mBSA-injected knees
were analyzed by marker staining and ﬂow cytometry. (C) Treg cells, (D) Th17 cells, (E) Breg cells, (F) IFN-γ-expressing CD4+ T cells and (G) CD8+ T
cells and (H) IL-10-producing CD4+ T cells were quantiﬁed and shown as mean ± SEM of n = 5 (PBS transfer), and n = 4 (T2 Breg-cell transfer) from
a single experiment performed. Statistical signiﬁcance determined by Student’s t-test.
B-cell populations. Deletion of Cdc42, the main effector of WASp,
has been described to result in signiﬁcantly reduced mature B-cell
populations and responsiveness to BAFF stimulation [40], favor-
ing involvement of WASp in BAFF receptor signaling events, but
this remains to be investigated.
Several studies have shown that WAS KO mice develop autoan-
tibodies and their presence has been linked with the develop-
ment of renal histopathology [7, 41, 42]. Similarly, increased
autoantibody production and autoimmunity have been demon-
strated in two models of B-cell-selective WASp deﬁciency suggest-
ing that there is a B-cell intrinsic role in WAS-related autoim-
munity [28, 43]. How this inﬂuences other autoreactive cell
populations is unclear. However, a subset of CD5+ B cells has
been identiﬁed to express high levels of Fas ligand [44]. These
cells also expressed IL-10 and further studies identiﬁed these as
Breg cells that played an important role in inducing apoptosis of
antigen-speciﬁc T cells, by cell–cell contact as well as Fas ligand
secretion [45].Moreover,CD5+ Fasligandpositive Bregcellswere
implicated in immune regulation in collagen-induced arthritis by
promoting apoptosis in arthritis-associated T cells [46].
In summary, our data demonstrate that the cytoskeletal regu-
lator WASp is required for acquisition of normal Breg-cell num-
bers and for normal function. This may have an important
inﬂuence on the balance and recruitment of Treg and Th17 cells
during inﬂammation. The mechanism by which Breg cells inﬂu-
ence experimental arthritis is not fully clear, although local secre-
tion of immunosuppressive cytokines such as IL-10, or control
of T-cell apoptosis remains attractive possibilities. Interestingly,
selective deﬁciency of WASp in Breg cells appears to be compen-
sated by intact functionality in other regulatory lineages, suggest-
ing that partial restoration of regulatory cell function in WAS may
be sufﬁcient toprotect oralleviate autoimmunity. Overall, itseems
likely that autoimmunity in WAS has a multicompartmental eti-
ology and that the contribution from different cell lineages may
depend on context and type of process involved.
Materials and methods
Mice
WAS KO and B/cWKO mice were bred in our own facilities
and C57BL/6 were purchased from Harlan. Mice were used at
6–12 weeks of age and all experiments approved by and per-
formed according to Home Ofﬁce Animal Welfare Legislation (PPL
70/7329).
Patients
Peripheral blood was obtained from WAS patients (Supporting
Information Table 1) and controls following informed consent
obtained in accordance with the Declaration of Helsinki and with
ethical approval from the Great Ormond Street Hospital for Chil-
dren and the Institute of Child Health Research Ethics. Human
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Figure 6. Reduced Breg cells in spleens of B/cWKO mice under naive, noninﬂammatory conditions. (A) Gating based on differential expression
of CD21 and CD23 on B220+ B cells is shown for marginal zone B cells (MZ) and T2-MZP Breg cells (Breg). Representative dotplots are shown. (B,
C) The number of (C) Breg cells and (C) MZ B cells in C57BL/6, WAS KO, and B/cWKO mice is shown as mean + SEM of n = 12 (C57BL/6), n = 11
(WAS KO), and n = 4 (B/cWKO) mice. (D) IL-10-expressing B cells isolated from spleens after stimulation with LPS for 24 h was assessed by ﬂow
cytometry. Top panels show IgG controls and bottom panels show gating for IL-10-producing CD19+ B cells. Representative dot plots are shown.
(E)The percentage of IL-10-expressing B cells is shown as mean + SEM of n = 8 (C57BL/6), n = 8 (WAS KO), and n = 4 (B/cWKO) mice pooled from
six experiments. Statistical signiﬁcance determined by Student’s t-test.
PBMCs were isolated using Ficoll-Hypaque (Amersham Pharma-
cia, Little Chalfont, UK) gradient centrifugation.
Induction and assessment of arthritis
Mice were immunized s.c. with endotoxin-free mBSA (1 μg/mL;
Sigma-Aldrich, Steinheim, Germany) in complete Freund’s adju-
vant and 7–10 days later challenged by intraarticular injection of
10 μLm B S A( 2 0μg/mL) in one knee and PBS in the other knee.
The development of arthritis was assessed daily in a blinded man-
ner. Clinical severity was determined by assessment of the ability
of the animals to walk normally (walking score) and graded as
follows: 0, normal; 1, limping; 2, severe limping causing the ani-
mal to hop; 3, refusal to put weight on leg; 4, refusing to walk
at all. In addition, swelling of both knee joints was measured
daily using calipers (knee swelling). Animals were sacriﬁced at
days 4 and 7 for analysis of immune cell populations in draining
LNs and spleen. Knee joints were removed postmortem, ﬁxed in
10% formalin (Sigma-Aldrich), embedded in parafﬁn followed by
sectioning and H&E staining.
Flow cytometric analysis
Single-cell suspensions were prepared from spleen and inguinal
LNs and cultured in RPMI with 10% FCS supplemented with
100 units/mL penicillin and 100 μg/mL (Invitrogen, Paisley,
UK). For analysis of steady state Breg cells, splenocytes were
stained with antibodies against CD21 (FITC), CD23 (PE), B220
(allophycocyanin). All antibodies were from BD Biosciences
(Erembodegem, Belgium), unless stated otherwise. For analysis of
IL-10-producing cells, splenocytes or CD19-selected B cells (CD19
selection beads, Miltenyi Biotec, Bergisch Gladbach, Germany)
werestimulatedwith100ng/mLLPS(Sigma-Aldrich)for24hand
PMA (50 ng/mL; Sigma-Aldrich), ionomycin (500 ng/mL; Sigma-
Aldrich), and brefeldin A (5 μg/mL; Sigma-Aldrich) were added
for the last 4–6 h. Cells were then stained with PerCP-conjugated
anti-B220, followed by permeabilization (BD Fix/Perm) and intra-
cellular stain with APC-conjugated anti-IL-10 or APC-conjugated
isotype control. For analysis of BAFF stimulation, CD19-selected
B cells were stimulated with the indicated concentrations of
recombinant mouse BAFF (Enzo Life Sciences, Exeter, UK) for
72 h followed by analysis of cell viability using 7AAD stain-
ing, analysis of BAFF-R (eBioscience, San Diego, CA, USA)
and IL-10 expression by ﬂow cytometry. Cells from arthritic
mice were cultured in vitro for 5 h with PMA, ionomycin,
and brefeldin A and then stained with antibodies against B220
(PerCP), CD4 (FITC), CD8 (PerCP), and CD25 (PE) followed
by permeabilization (BD Fix/Perm or FoxP3-speciﬁc permeabi-
lization reagents from eBioscience) and intracellular staining
for FoxP3 (allophycocyanin; eBioscience), IL-17 (PE; Miltenyi
Biotec), IFN-γ (allophycocyanin), or appropriately conjugated iso-
type controls. For analysis of B10 Breg cells, splenocytes were
stained with PE-Cy7 anti-CD19, PE anti-CD1d, and FITC anti-
CD5. Human PBMC was stained with antibodies against CD19
(PerCP-Cy5.5), CD24 (FITC), and CD38 (PE) or stimulated for
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Figure 7. B/cWKO mice do not develop severe arthritis despite having reduced numbers of Breg cells. (A, B) Experimental arthritis development
was assessed by (A) clinical walking score and (B) knee swelling. (C–H) The indicated cell populations in the draining LNs of mBSA-injected knees
were analyzed by marker staining and ﬂow cytometry. The numbers of (C) Treg cells, (D) Th17 cells, (E) Breg cells, (F) IFN-γ-expressing CD4+ T
cells and (G) CD8+ T cells, and (H) IL-10-producing CD4+ T cells are shown as mean ± SEM of n = 8 (C57BL/6), n = 8 (B/cWKO), and n = 3 (WAS KO)
mice pooled from two experiments. (I, J) The frequency of Treg cells were analyzed under noninﬂammatory conditions in (I) spleen and (J) LNs
and shown as mean ± SEM of n = 5 (C57BL/6), n = 3 (B/cWKO), and n = 4 (WAS KO) mice pooled from two independent experiments. Statistical
signiﬁcance determined by Student’s t-test.
48 h with 0.1 μM CpG (Invivogen, San Diego, CA, USA) and the
last 4–6 h with PMA, ionomycin, and brefeldin A followed by stain-
ing with antibodies against CD19 (PerCP-Cy5.5), CD24 (FITC),
CD38 (PE), permeabilization (BD Fix/Perm), and intracellular
staining with anti-IL-10 (allophycocyanin). Cells were acquired
with a Cyan cytometer (Dako Cytomation, Glostrup, Denmark)
and analyzed with FlowJo software (Treestar, Ashland, OR, USA).
Adoptive transfer
Splenocytes were isolated from 19 C57BL/6 mice that were
preimmunized with mBSA and challenged intraarticularly with
mBSA as described above, and depleted for CD43+ cells using
microbeads and LD columns (Miltenyi Biotec). The resulting cells
werestainedwithanti-CD21-FITC,anti-CD23-PE,anti-CD4-biotin,
streptavidin-allophycocyanin, and CD19-PE-Cy7 (BD Biosciences)
and sorted by a FACS Aria cell sorter (Beckman Coulter, Brea, CA,
USA) for CD19+CD21+CD23+CD24hi Breg cells that were subse-
quently injected (1.7 × 106) into the tail veins of C57BL/6 or WAS
KO recipients at the time of intraknee mBSA challenge. Develop-
ment of arthritis was assessed daily by knee swelling measurement
and clinical assessment and animals were sacriﬁced at day 3 for
analysis of immune cell populations in the draining LNs.
T-cell suppression
CD4+CD25hi natural Treg cells and CD4+CD25− target cells were
puriﬁed from spleens of B/cWKO and control littermates by ﬂow
cytometry as previously reported [6]. T-cell-depleted spleen cells
(feeder cells) were obtained from control splenocytes by mag-
netic depletion of CD3+ cells (Miltenyi Biotec). Suppression assays
were performed in triplicate using 25 000 CD4+CD25− target cells
from control littermate spleens, 250 000 irradiated (30 Gy) feeder
cells and 25 000 (ratio 1:1) or 5000 (ratio 1:5) CD4+CD25+ nat-
ural T regulatory cells from B/cWKO or C57BL/6 mice in the
presence of soluble anti-CD3 and anti-CD28 Abs (1 μg/mL each;
BD Biosciences). After 4 days, cultures were pulsed with μCi
[3H]thymidine (GE Healthcare, Buckinghamshire, UK) for 16 h
before harvesting and measurement of the incorporated radioac-
tivity by scintillation counting (Perkin Elmer, Buckinghamshire,
UK).
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Statistical analysis
Data are expressed as mean ± SEM and analyzed using Student’s
t-test or one-way ANOVA of the area under the curve. All statistical
tests were performed using Prims 5 (GraphPad). p Values < 0.05
were considered as statistically signiﬁcant.
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